Jounce Therapeutics Inc JNCE:NASDAQ

Last Price$4.65Cboe Real-Time Last Sale as of 12:11PM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.14(2.92%)
Bid (Size)$4.62 (200)
Ask (Size)$4.66 (346)
Day Low / High$4.60 - 4.82
Volume37.8 K
 

View Biotechnology IndustryPeer Comparison as of 08/17/2022

 

Jounce Therapeutics Inc ( NASDAQ )

Price: $4.65
Change: -0.14 (2.92%)
Volume: 37.8 K
12:11PM ET 8/17/2022
 
 

Lineage Cell Therapeutics Inc ( NYSE MKT LLC )

Price: $1.49
Change: -0.02 (1.32%)
Volume: 175.4 K
11:49AM ET 8/17/2022
 
 

Verastem Inc ( NASDAQ )

Price: $1.35
Change: -0.03 (1.82%)
Volume: 330.7 K
12:17PM ET 8/17/2022
 
 

Voyager Therapeutics Inc ( NASDAQ )

Price: $5.91
Change: -0.17 (2.80%)
Volume: 30.1 K
12:02PM ET 8/17/2022
 
 

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.67
Change: -0.06 (0.69%)
Volume: 3.1 K
12:14PM ET 8/17/2022
 

Read more news Recent News

--HC Wainwright Lowers Jounce Therapeutics Price Target to $11 From $15, Buy Rating Maintained
9:34AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Piper Sandler Lowers Jounce Therapeutics' Price Target to $9 From $17, Maintains Overweight Rating
9:56AM ET 5/23/2022 MT Newswires

Jounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $7 to $20, according to analysts polled by Capital IQ. (MT...

Jounce Therapeutics' Shares Drop After Baird Downgrade
2:10PM ET 5/11/2022 MT Newswires

Shares of Jounce Therapeutics (JNCE) were down almost 19% in Wednesday afternoon trading after Baird downgraded the clinical-stage drugmaker's stock to...

--Baird Downgrades Jounce Therapeutics to Neutral From Outperform, Adjusts Price Target to $7 From $15
7:23AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. View company web site for more details
Address780 Memorial Drive
Cambridge, Massachusetts 02139
Phone+1.857.259.3840
Number of Employees115
Recent SEC Filing08/04/202210-Q
President, Chief Executive Officer & DirectorRichard Murray
Chief Operating OfficerHugh M. Cole
Chief Financial Officer & TreasurerKimberlee Cobleigh Drapkin
Chief Medical OfficerElizabeth G. Trehu

Company Highlights

Price Open$4.64
Previous Close$4.79
52 Week Range$2.76 - 9.81
Market Capitalization$240.4 M
Shares Outstanding51.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.55
Beta vs. S&P 500N/A
Revenue$65.2 M
Net Profit MarginN/A
Return on Equity-63.86%

Analyst Ratings as of 07/29/2022

Buy
5
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset